Skip to main content
Top
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil

Authors: JJD Furtado, JV Madruga, EL Bicudo, M Eira, MIB Lopes, EM Netto, MS de Oliveira, OHM Leite, AA Machado, U Tupinambas, JL de Andrade Neto, MPJ Lima, DB Wajsbrot, LM Cassoli

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

MVC is the first-in-class CCR5 antagonist approved for use in treatment of CCR5-tropic (R5) HIV-1 infection; however, there is limited experience with MVC in regimens containing newer PIs and other new agents. This open-label 96-week multi-center study evaluates MVC in a variety of regimens to obtain additional safety and efficacy data in TE patients with limited options due to intolerance or resistance in Brazil. …
Metadata
Title
Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
Authors
JJD Furtado
JV Madruga
EL Bicudo
M Eira
MIB Lopes
EM Netto
MS de Oliveira
OHM Leite
AA Machado
U Tupinambas
JL de Andrade Neto
MPJ Lima
DB Wajsbrot
LM Cassoli
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P105

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue